data_2mfo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mfo _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 120.754 0.311 . . . . 2.4199999999999999 110.977 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -73.81 -37.48 64.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.455 -0.339 . . . . 3.4700000000000002 111.468 -176.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.452 ' C ' ' H ' ' A' ' 5' ' ' THR . 0.6 OUTLIER . . . . . 0 C--N 1.322 -0.606 0 N-CA-C 110.059 -0.349 . . . . 2.5699999999999998 110.059 178.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.452 ' H ' ' C ' ' A' ' 3' ' ' GLN . 82.1 p . . . . . 0 N--CA 1.469 0.486 0 N-CA-C 113.432 0.901 . . . . 2.3100000000000001 113.432 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -141.39 72.86 25.78 Favored Pre-proline 0 C--N 1.309 -1.156 0 CA-C-N 115.26 -0.882 . . . . 2.7000000000000002 110.498 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.45 162.12 43.17 Favored 'Trans proline' 0 C--O 1.234 0.288 0 C-N-CA 123.218 2.612 . . . . 1.49 112.238 -175.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.76 31.08 27.69 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.591 -0.814 . . . . 1.1699999999999999 112.228 -176.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.7 p30 41.01 42.43 1.53 Allowed 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.231 1.012 . . . . 4.7199999999999998 113.039 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.4 m . . . . . 0 CA--C 1.539 0.553 0 CA-C-N 116.5 -0.318 . . . . 2.98 111.421 178.78 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.458 0 N-CA-C 112.437 -0.265 . . . . 2.3399999999999999 112.437 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.12 133.33 53.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 110.047 -0.353 . . . . 2.6600000000000001 110.047 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.09 -173.4 43.55 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.918 -0.658 . . . . 2.1000000000000001 111.604 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 76.1 t60 . . . . . 0 C--O 1.242 0.699 0 CA-C-O 118.561 -0.733 . . . . 6.6299999999999999 109.76 179.252 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.132 0 CA-C-O 120.423 0.154 . . . . 2.4199999999999999 110.975 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -66.25 -41.3 90.13 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 121.195 0.521 . . . . 3.4700000000000002 110.33 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.521 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.689 0 CA-C-N 115.599 -0.728 . . . . 2.5699999999999998 109.395 175.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p . . . . . 0 N--CA 1.466 0.369 0 N-CA-C 112.539 0.57 . . . . 2.3100000000000001 112.539 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.458 ' HG1' ' HB3' ' A' ' 10' ' ' SER . 14.7 p 45.5 68.5 3.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 113.044 0.757 . . . . 2.7000000000000002 113.044 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.438 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.9 Cg_exo -59.39 118.68 5.6 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.868 2.379 . . . . 1.49 111.914 177.283 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.3 -35.07 2.66 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.507 -0.769 . . . . 1.1699999999999999 111.196 -177.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.2 t30 -171.17 107.57 0.27 Allowed 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.962 -0.384 . . . . 4.7199999999999998 109.962 177.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.458 ' HB3' ' HG1' ' A' ' 6' ' ' THR . 21.9 p . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 2.98 109.992 -179.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.503 0 N-CA-C 111.372 -0.691 . . . . 2.3399999999999999 111.372 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.54 HG12 ' H ' ' A' ' 14' ' ' GLY . 2.7 p -166.78 -65.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 110.063 -0.347 . . . . 2.6600000000000001 110.063 175.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.54 ' H ' HG12 ' A' ' 13' ' ' VAL . . . 78.29 130.63 0.59 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.779 -0.724 . . . . 2.1000000000000001 112.689 177.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 . . . . . 0 C--O 1.246 0.873 0 CA-C-O 118.597 -0.716 . . . . 6.6299999999999999 109.849 -178.127 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.121 0 CA-C-O 120.684 0.278 . . . . 2.4199999999999999 110.49 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -69.38 -38.74 78.15 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 121.775 0.797 . . . . 3.4700000000000002 109.138 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.513 ' HG3' ' HG3' ' A' ' 7' ' ' PRO . 0.2 OUTLIER . . . . . 0 N--CA 1.443 -0.819 0 CA-C-N 114.254 -1.339 . . . . 2.5699999999999998 109.384 177.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 66.8 p . . . . . 0 N--CA 1.467 0.415 0 N-CA-C 112.679 0.622 . . . . 2.3100000000000001 112.679 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 t -48.49 113.47 2.92 Favored Pre-proline 0 CA--C 1.535 0.402 0 C-N-CA 123.352 0.661 . . . . 2.7000000000000002 112.316 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.525 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 69.2 Cg_exo -57.5 156.63 25.7 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 123.342 2.695 . . . . 1.49 113.094 176.358 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.95 -39.58 2.7 Favored Glycine 0 N--CA 1.447 -0.626 0 CA-C-N 115.425 -0.807 . . . . 1.1699999999999999 111.885 -177.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -133.29 24.96 4.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.529 0.681 . . . . 4.7199999999999998 109.914 -177.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.525 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.3 m . . . . . 0 C--N 1.321 -0.649 0 CA-C-N 115.271 -0.877 . . . . 2.98 111.191 -176.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.393 0 N-CA-C 112.374 -0.29 . . . . 2.3399999999999999 112.374 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.5 t -97.32 -68.4 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 110.22 -0.289 . . . . 2.6600000000000001 110.22 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.68 49.36 56.04 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.716 -0.754 . . . . 2.1000000000000001 113.131 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 t60 . . . . . 0 C--O 1.244 0.796 0 CA-C-O 118.474 -0.774 . . . . 6.6299999999999999 109.943 177.245 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.652 0.263 . . . . 2.4199999999999999 110.802 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -129.56 25.2 5.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.349 0.595 . . . . 3.4700000000000002 109.879 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 13.3 pm0 . . . . . 0 C--N 1.322 -0.627 0 CA-C-N 115.56 -0.746 . . . . 2.5699999999999998 109.629 -179.89 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.8 p . . . . . 0 N--CA 1.469 0.495 0 CA-C-O 121.354 0.597 . . . . 2.3100000000000001 111.994 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 4.3 t 176.05 103.56 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.99 -1.004 . . . . 2.7000000000000002 110.086 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -81.45 -171.42 1.21 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.859 2.373 . . . . 1.49 112.149 175.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 90.09 -1.45 80.22 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 121.019 -0.61 . . . . 1.1699999999999999 112.714 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 60.66 71.76 0.55 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.232 0.539 . . . . 4.7199999999999998 110.597 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.0 m . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.0 -0.546 . . . . 2.98 111.631 179.55 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.59 0 N-CA-C 112.279 -0.329 . . . . 2.3399999999999999 112.279 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.61 163.88 17.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 110.087 -0.338 . . . . 2.6600000000000001 110.087 -179.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.92 152.48 5.65 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.426 -0.67 . . . . 2.1000000000000001 111.426 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.672 -0.68 . . . . 6.6299999999999999 109.825 -178.215 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.039 0 CA-C-O 120.579 0.228 . . . . 2.4199999999999999 110.967 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.58 -72.4 0.71 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.128 0.489 . . . . 3.4700000000000002 109.884 179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.513 ' HG3' ' HG3' ' A' ' 7' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.446 -0.636 0 CA-C-N 115.649 -0.705 . . . . 2.5699999999999998 109.48 175.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.6 p . . . . . 0 N--CA 1.469 0.5 0 N-CA-C 111.739 0.274 . . . . 2.3100000000000001 111.739 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.5 p -50.7 123.76 18.59 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.317 -0.401 . . . . 2.7000000000000002 112.05 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.513 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.8 Cg_exo -56.14 156.72 19.51 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.063 2.509 . . . . 1.49 112.517 176.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 95.5 82.74 1.61 Allowed Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 111.408 -0.677 . . . . 1.1699999999999999 111.408 -177.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 69.19 42.83 1.17 Allowed 'General case' 0 CA--C 1.52 -0.188 0 CA-C-O 121.566 0.698 . . . . 4.7199999999999998 109.752 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.617 ' OG ' ' HA3' ' A' ' 14' ' ' GLY . 4.4 m . . . . . 0 C--N 1.322 -0.622 0 CA-C-N 114.988 -1.006 . . . . 2.98 110.42 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.634 0 N-CA-C 111.349 -0.701 . . . . 2.3399999999999999 111.349 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.5 p -165.36 122.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.073 0.463 . . . . 2.6600000000000001 110.497 177.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.617 ' HA3' ' OG ' ' A' ' 10' ' ' SER . . . -159.95 135.03 3.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.579 -0.82 . . . . 2.1000000000000001 112.885 -178.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 69.6 m80 . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.353 -0.832 . . . . 6.6299999999999999 109.838 177.958 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.986 0 N-CA-C 110.557 -0.164 . . . . 2.4199999999999999 110.557 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 67.67 -75.82 0.06 Allowed 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 123.679 0.792 . . . . 3.4700000000000002 111.258 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 116.439 -0.346 . . . . 2.5699999999999998 110.345 179.14 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.8 p . . . . . 0 N--CA 1.467 0.392 0 N-CA-C 112.737 0.643 . . . . 2.3100000000000001 112.737 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.7 t 36.85 65.37 2.35 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 124.377 1.071 . . . . 2.7000000000000002 113.203 179.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -59.2 132.37 46.45 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.727 2.285 . . . . 1.49 111.718 175.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.401 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 122.14 -47.17 1.04 Allowed Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.265 -1.134 . . . . 1.1699999999999999 110.265 -171.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -164.67 105.8 0.84 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.894 -0.41 . . . . 4.7199999999999998 109.894 175.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.436 ' HG ' ' N ' ' A' ' 14' ' ' GLY . 86.8 p . . . . . 0 C--N 1.322 -0.617 0 N-CA-C 108.798 -0.816 . . . . 2.98 108.798 176.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.441 0 N-CA-C 111.838 -0.505 . . . . 2.3399999999999999 111.838 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.1 t -135.69 -86.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 2.6600000000000001 110.157 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.436 ' N ' ' HG ' ' A' ' 10' ' ' SER . . . 82.3 109.99 0.43 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.79 -0.719 . . . . 2.1000000000000001 111.892 -177.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 4.0 p80 . . . . . 0 C--O 1.245 0.816 0 CA-C-O 118.378 -0.82 . . . . 6.6299999999999999 109.873 -179.636 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.182 0 CA-C-O 120.438 0.161 . . . . 2.4199999999999999 110.919 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -66.69 -53.43 33.7 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.043 0.449 . . . . 3.4700000000000002 110.364 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.445 ' HG3' ' HG3' ' A' ' 7' ' ' PRO . 5.1 pm0 . . . . . 0 N--CA 1.445 -0.681 0 CA-C-N 115.9 -0.591 . . . . 2.5699999999999998 109.785 176.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p . . . . . 0 N--CA 1.465 0.312 0 N-CA-C 110.547 -0.168 . . . . 2.3100000000000001 110.547 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.9 t -41.3 109.95 0.7 Allowed Pre-proline 0 CA--C 1.539 0.554 0 O-C-N 123.602 0.564 . . . . 2.7000000000000002 111.763 177.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.445 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 2.7 Cg_exo -75.98 -166.96 0.4 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.937 2.425 . . . . 1.49 112.79 -177.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.0 24.17 62.3 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.98 -0.628 . . . . 1.1699999999999999 111.696 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 62.12 28.35 17.08 Favored 'General case' 0 C--N 1.333 -0.151 0 C-N-CA 122.748 0.419 . . . . 4.7199999999999998 111.372 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.9 m . . . . . 0 CA--C 1.537 0.472 0 CA-C-N 116.356 -0.384 . . . . 2.98 111.404 179.21 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 N-CA-C 111.826 -0.51 . . . . 2.3399999999999999 111.826 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.3 p -138.35 166.43 23.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.969 -0.382 . . . . 2.6600000000000001 109.969 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.15 159.16 10.16 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.034 -0.603 . . . . 2.1000000000000001 112.002 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 7.9 p80 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.454 -0.784 . . . . 6.6299999999999999 110.269 -178.072 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.06 0 N-CA-C 110.094 -0.336 . . . . 2.4199999999999999 110.094 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -61.75 -29.44 70.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.735 0.302 . . . . 3.4700000000000002 110.936 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 . . . . . 0 C--N 1.325 -0.498 0 N-CA-C 109.765 -0.457 . . . . 2.5699999999999998 109.765 175.127 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 43.6 p . . . . . 0 N--CA 1.468 0.461 0 N-CA-C 112.155 0.428 . . . . 2.3100000000000001 112.155 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.473 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 4.5 t -40.42 105.85 0.39 Allowed Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 123.948 0.78 . . . . 2.7000000000000002 111.784 -177.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.594 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 13.9 Cg_exo -71.17 83.79 0.94 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.106 2.538 . . . . 1.49 114.357 -170.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.81 -22.04 44.33 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 110.721 -0.952 . . . . 1.1699999999999999 110.721 168.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.8 m120 74.68 92.2 0.08 Allowed 'General case' 0 N--CA 1.465 0.318 0 C-N-CA 123.749 0.82 . . . . 4.7199999999999998 111.915 174.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 59.7 m . . . . . 0 CA--C 1.541 0.608 0 CA-C-N 116.055 -0.521 . . . . 2.98 111.943 174.798 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.643 0 N-CA-C 111.545 -0.622 . . . . 2.3399999999999999 111.545 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -84.18 47.94 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.444 0.64 . . . . 2.6600000000000001 111.617 -177.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.594 ' CA ' ' HA ' ' A' ' 7' ' ' PRO . . . 152.14 -159.84 28.57 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.558 -0.829 . . . . 2.1000000000000001 112.734 177.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 51.1 t-80 . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.27 -0.872 . . . . 6.6299999999999999 111.15 -177.959 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 120.688 0.28 . . . . 2.4199999999999999 110.758 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -63.5 -51.04 67.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.049 0.452 . . . . 3.4700000000000002 110.048 178.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 . . . . . 0 C--N 1.325 -0.476 0 CA-C-N 115.801 -0.636 . . . . 2.5699999999999998 109.52 174.781 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 35.8 p . . . . . 0 N--CA 1.468 0.471 0 N-CA-C 113.542 0.941 . . . . 2.3100000000000001 113.542 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.408 ' O ' ' HB2' ' A' ' 10' ' ' SER . 41.2 p 47.4 82.53 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 115.621 -0.718 . . . . 2.7000000000000002 112.105 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -79.33 -158.53 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.812 2.341 . . . . 1.49 111.753 -178.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.63 56.89 5.74 Favored Glycine 0 N--CA 1.447 -0.627 0 C-N-CA 120.352 -0.928 . . . . 1.1699999999999999 111.903 -176.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 56.1 t30 50.88 64.94 1.63 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.18 0.514 . . . . 4.7199999999999998 111.283 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.408 ' HB2' ' O ' ' A' ' 6' ' ' THR . 46.1 m . . . . . 0 C--N 1.322 -0.601 0 CA-C-N 116.303 -0.408 . . . . 2.98 111.087 175.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.547 0 N-CA-C 111.978 -0.449 . . . . 2.3399999999999999 111.978 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.8 m -83.59 47.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.407 0.622 . . . . 2.6600000000000001 111.702 -177.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.52 130.72 10.0 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.798 -0.715 . . . . 2.1000000000000001 111.944 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 . . . . . 0 C--O 1.247 0.921 0 CA-C-O 118.795 -0.622 . . . . 6.6299999999999999 109.777 -178.512 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.175 0 N-CA-C 109.92 -0.4 . . . . 2.4199999999999999 109.92 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -70.6 -31.72 68.81 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 108.646 -0.872 . . . . 3.4700000000000002 108.646 171.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 . . . . . 0 N--CA 1.445 -0.685 0 N-CA-C 107.927 -1.138 . . . . 2.5699999999999998 107.927 168.889 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.0 p . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 121.676 0.751 . . . . 2.3100000000000001 111.966 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.462 ' O ' HG21 ' A' ' 6' ' ' THR . 3.6 t 175.96 104.98 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 114.415 -1.266 . . . . 2.7000000000000002 108.546 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.475 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 8.7 Cg_endo -97.49 171.74 0.74 Allowed 'Trans proline' 0 CA--C 1.533 0.437 0 C-N-CA 123.702 2.935 . . . . 1.49 113.786 178.384 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.49 1.8 63.93 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.936 -0.574 . . . . 1.1699999999999999 113.637 172.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.1 p30 172.71 39.38 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 108.69 -0.856 . . . . 4.7199999999999998 108.69 -176.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.475 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.1 m . . . . . 0 C--N 1.312 -1.044 0 CA-C-N 114.804 -1.089 . . . . 2.98 112.461 -164.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.542 0 N-CA-C 112.196 -0.361 . . . . 2.3399999999999999 112.196 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.35 -85.13 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 120.688 0.28 . . . . 2.6600000000000001 110.961 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.08 165.57 37.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.942 -0.647 . . . . 2.1000000000000001 112.493 -178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 . . . . . 0 C--O 1.246 0.902 0 CA-C-O 118.097 -0.954 . . . . 6.6299999999999999 110.321 179.106 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 120.754 0.311 . . . . 2.4199999999999999 110.977 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -73.81 -37.48 64.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.455 -0.339 . . . . 3.4700000000000002 111.468 -176.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.452 ' C ' ' H ' ' A' ' 5' ' ' THR . 0.6 OUTLIER -87.42 134.46 33.59 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.059 -0.349 . . . . 2.5699999999999998 110.059 178.804 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.467 ' C ' ' HG1' ' A' ' 5' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.467 ' HG1' ' C ' ' A' ' 4' ' ' HZP . 82.1 p 53.13 17.15 0.9 Allowed 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 125.087 1.355 . . . . 2.3100000000000001 113.432 177.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -141.39 72.86 25.78 Favored Pre-proline 0 C--N 1.309 -1.156 0 CA-C-N 115.26 -0.882 . . . . 2.7000000000000002 110.498 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.45 162.12 43.17 Favored 'Trans proline' 0 C--O 1.234 0.288 0 C-N-CA 123.218 2.612 . . . . 1.49 112.238 -175.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.76 31.08 27.69 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.591 -0.814 . . . . 1.1699999999999999 112.228 -176.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.7 p30 41.01 42.43 1.53 Allowed 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.231 1.012 . . . . 4.7199999999999998 113.039 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.521 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 14.4 m -61.66 -47.37 85.65 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 116.5 -0.318 . . . . 2.98 111.421 178.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.521 ' HD ' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.84 -49.22 1.28 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.965 -0.636 . . . . 2.3399999999999999 112.437 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.12 133.33 53.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 110.047 -0.353 . . . . 2.6600000000000001 110.047 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.09 -173.4 43.55 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.918 -0.658 . . . . 2.1000000000000001 111.604 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 76.1 t60 . . . . . 0 C--O 1.242 0.699 0 CA-C-O 118.561 -0.733 . . . . 6.6299999999999999 109.76 179.252 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.132 0 CA-C-O 120.423 0.154 . . . . 2.4199999999999999 110.975 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -66.25 -41.3 90.13 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 121.195 0.521 . . . . 3.4700000000000002 110.33 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.521 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER -91.57 124.46 35.74 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.599 -0.728 . . . . 2.5699999999999998 109.395 175.843 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p 60.56 163.92 0.07 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 124.632 1.173 . . . . 2.3100000000000001 112.539 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.458 ' HG1' ' HB3' ' A' ' 10' ' ' SER . 14.7 p 45.5 68.5 3.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 113.044 0.757 . . . . 2.7000000000000002 113.044 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.438 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.9 Cg_exo -59.39 118.68 5.6 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.868 2.379 . . . . 1.49 111.914 177.283 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.3 -35.07 2.66 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.507 -0.769 . . . . 1.1699999999999999 111.196 -177.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.2 t30 -171.17 107.57 0.27 Allowed 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.962 -0.384 . . . . 4.7199999999999998 109.962 177.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.458 ' HB3' ' HG1' ' A' ' 6' ' ' THR . 21.9 p -141.78 167.15 22.84 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 2.98 109.992 -179.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.457 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.26 -67.97 1.78 Allowed Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.63 -0.795 . . . . 2.3399999999999999 111.372 176.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.54 HG12 ' H ' ' A' ' 14' ' ' GLY . 2.7 p -166.78 -65.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 110.063 -0.347 . . . . 2.6600000000000001 110.063 175.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.54 ' H ' HG12 ' A' ' 13' ' ' VAL . . . 78.29 130.63 0.59 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.779 -0.724 . . . . 2.1000000000000001 112.689 177.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 . . . . . 0 C--O 1.246 0.873 0 CA-C-O 118.597 -0.716 . . . . 6.6299999999999999 109.849 -178.127 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.121 0 CA-C-O 120.684 0.278 . . . . 2.4199999999999999 110.49 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -69.38 -38.74 78.15 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 121.775 0.797 . . . . 3.4700000000000002 109.138 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.513 ' HG3' ' HG3' ' A' ' 7' ' ' PRO . 0.2 OUTLIER -96.33 157.18 16.02 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-N 114.254 -1.339 . . . . 2.5699999999999998 109.384 177.104 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.539 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.452 ' HG1' ' C ' ' A' ' 4' ' ' HZP . 66.8 p 60.66 -173.18 0.13 Allowed 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 124.791 1.236 . . . . 2.3100000000000001 112.679 178.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 t -48.49 113.47 2.92 Favored Pre-proline 0 CA--C 1.535 0.402 0 C-N-CA 123.352 0.661 . . . . 2.7000000000000002 112.316 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.525 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 69.2 Cg_exo -57.5 156.63 25.7 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 123.342 2.695 . . . . 1.49 113.094 176.358 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.95 -39.58 2.7 Favored Glycine 0 N--CA 1.447 -0.626 0 CA-C-N 115.425 -0.807 . . . . 1.1699999999999999 111.885 -177.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -133.29 24.96 4.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.529 0.681 . . . . 4.7199999999999998 109.914 -177.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.539 ' HB3' ' O ' ' A' ' 4' ' ' HZP . 1.3 m -76.58 149.46 36.61 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.271 -0.877 . . . . 2.98 111.191 -176.234 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.32 -66.15 0.28 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.737 -0.744 . . . . 2.3399999999999999 112.374 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.5 t -97.32 -68.4 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 110.22 -0.289 . . . . 2.6600000000000001 110.22 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.68 49.36 56.04 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.716 -0.754 . . . . 2.1000000000000001 113.131 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 t60 . . . . . 0 C--O 1.244 0.796 0 CA-C-O 118.474 -0.774 . . . . 6.6299999999999999 109.943 177.245 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.652 0.263 . . . . 2.4199999999999999 110.802 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -129.56 25.2 5.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.349 0.595 . . . . 3.4700000000000002 109.879 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 13.3 pm0 -130.58 147.01 52.21 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.56 -0.746 . . . . 2.5699999999999998 109.629 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.402 ' O ' HG21 ' A' ' 6' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.8 p 56.33 28.13 12.96 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.393 1.077 . . . . 2.3100000000000001 111.994 -178.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.402 HG21 ' O ' ' A' ' 4' ' ' HZP . 4.3 t 176.05 103.56 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.99 -1.004 . . . . 2.7000000000000002 110.086 178.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -81.45 -171.42 1.21 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.859 2.373 . . . . 1.49 112.149 175.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 90.09 -1.45 80.22 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 121.019 -0.61 . . . . 1.1699999999999999 112.714 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 60.66 71.76 0.55 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.232 0.539 . . . . 4.7199999999999998 110.597 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.527 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 19.0 m -114.57 -53.24 2.67 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.0 -0.546 . . . . 2.98 111.631 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.527 ' HD ' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.83 -58.86 0.57 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.869 -0.682 . . . . 2.3399999999999999 112.279 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.61 163.88 17.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 110.087 -0.338 . . . . 2.6600000000000001 110.087 -179.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.92 152.48 5.65 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.426 -0.67 . . . . 2.1000000000000001 111.426 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.672 -0.68 . . . . 6.6299999999999999 109.825 -178.215 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.039 0 CA-C-O 120.579 0.228 . . . . 2.4199999999999999 110.967 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.58 -72.4 0.71 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.128 0.489 . . . . 3.4700000000000002 109.884 179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.513 ' HG3' ' HG3' ' A' ' 7' ' ' PRO . 0.0 OUTLIER -97.11 146.05 25.41 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.649 -0.705 . . . . 2.5699999999999998 109.48 175.989 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.451 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.6 p 70.06 -171.04 0.17 Allowed 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 125.18 1.392 . . . . 2.3100000000000001 111.739 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.5 p -50.7 123.76 18.59 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.317 -0.401 . . . . 2.7000000000000002 112.05 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.513 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.8 Cg_exo -56.14 156.72 19.51 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.063 2.509 . . . . 1.49 112.517 176.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 95.5 82.74 1.61 Allowed Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 111.408 -0.677 . . . . 1.1699999999999999 111.408 -177.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 69.19 42.83 1.17 Allowed 'General case' 0 CA--C 1.52 -0.188 0 CA-C-O 121.566 0.698 . . . . 4.7199999999999998 109.752 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.617 ' OG ' ' HA3' ' A' ' 14' ' ' GLY . 4.4 m -76.53 148.27 37.21 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.988 -1.006 . . . . 2.98 110.42 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 123.63 -70.87 0.44 Allowed Glycine 0 N--CA 1.446 -0.634 0 N-CA-C 111.349 -0.701 . . . . 2.3399999999999999 111.349 -176.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.5 p -165.36 122.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.073 0.463 . . . . 2.6600000000000001 110.497 177.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.617 ' HA3' ' OG ' ' A' ' 10' ' ' SER . . . -159.95 135.03 3.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.579 -0.82 . . . . 2.1000000000000001 112.885 -178.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 69.6 m80 . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.353 -0.832 . . . . 6.6299999999999999 109.838 177.958 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.986 0 N-CA-C 110.557 -0.164 . . . . 2.4199999999999999 110.557 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 67.67 -75.82 0.06 Allowed 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 123.679 0.792 . . . . 3.4700000000000002 111.258 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -80.09 126.33 30.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.439 -0.346 . . . . 2.5699999999999998 110.345 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.499 ' C ' ' HG1' ' A' ' 5' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.499 ' HG1' ' C ' ' A' ' 4' ' ' HZP . 61.8 p 57.78 -175.22 0.08 Allowed 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.445 1.098 . . . . 2.3100000000000001 112.737 176.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.7 t 36.85 65.37 2.35 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 124.377 1.071 . . . . 2.7000000000000002 113.203 179.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -59.2 132.37 46.45 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.727 2.285 . . . . 1.49 111.718 175.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.401 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 122.14 -47.17 1.04 Allowed Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.265 -1.134 . . . . 1.1699999999999999 110.265 -171.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -164.67 105.8 0.84 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.894 -0.41 . . . . 4.7199999999999998 109.894 175.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.436 ' HG ' ' N ' ' A' ' 14' ' ' GLY . 86.8 p -131.04 158.97 38.9 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.798 -0.816 . . . . 2.98 108.798 176.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.63 -74.48 0.69 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.819 -0.705 . . . . 2.3399999999999999 111.838 177.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.1 t -135.69 -86.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 2.6600000000000001 110.157 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.436 ' N ' ' HG ' ' A' ' 10' ' ' SER . . . 82.3 109.99 0.43 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.79 -0.719 . . . . 2.1000000000000001 111.892 -177.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 4.0 p80 . . . . . 0 C--O 1.245 0.816 0 CA-C-O 118.378 -0.82 . . . . 6.6299999999999999 109.873 -179.636 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.182 0 CA-C-O 120.438 0.161 . . . . 2.4199999999999999 110.919 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -66.69 -53.43 33.7 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.043 0.449 . . . . 3.4700000000000002 110.364 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.445 ' HG3' ' HG3' ' A' ' 7' ' ' PRO . 5.1 pm0 -84.3 141.44 30.93 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-N 115.9 -0.591 . . . . 2.5699999999999998 109.785 176.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.449 ' C ' ' HG1' ' A' ' 5' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.449 ' HG1' ' C ' ' A' ' 4' ' ' HZP . 82.7 p 55.34 -161.83 0.16 Allowed 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 123.602 0.761 . . . . 2.3100000000000001 110.547 -175.127 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.497 ' O ' ' HD ' ' A' ' 11' ' ' HZP . 2.9 t -41.3 109.95 0.7 Allowed Pre-proline 0 CA--C 1.539 0.554 0 O-C-N 123.602 0.564 . . . . 2.7000000000000002 111.763 177.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.445 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 2.7 Cg_exo -75.98 -166.96 0.4 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.937 2.425 . . . . 1.49 112.79 -177.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.0 24.17 62.3 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.98 -0.628 . . . . 1.1699999999999999 111.696 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 62.12 28.35 17.08 Favored 'General case' 0 C--N 1.333 -0.151 0 C-N-CA 122.748 0.419 . . . . 4.7199999999999998 111.372 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.491 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 15.9 m -65.75 -48.86 70.47 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.356 -0.384 . . . . 2.98 111.404 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.497 ' HD ' ' O ' ' A' ' 6' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 118.6 -38.1 3.0 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.401 -0.818 . . . . 2.3399999999999999 111.826 -179.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.3 p -138.35 166.43 23.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.969 -0.382 . . . . 2.6600000000000001 109.969 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.15 159.16 10.16 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.034 -0.603 . . . . 2.1000000000000001 112.002 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 7.9 p80 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.454 -0.784 . . . . 6.6299999999999999 110.269 -178.072 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.06 0 N-CA-C 110.094 -0.336 . . . . 2.4199999999999999 110.094 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -61.75 -29.44 70.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.735 0.302 . . . . 3.4700000000000002 110.936 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 -102.79 141.99 34.67 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.765 -0.457 . . . . 2.5699999999999998 109.765 175.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.408 ' C ' ' HG1' ' A' ' 5' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.408 ' HG1' ' C ' ' A' ' 4' ' ' HZP . 43.6 p 67.56 -171.8 0.19 Allowed 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 124.438 1.095 . . . . 2.3100000000000001 112.155 171.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.473 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 4.5 t -40.42 105.85 0.39 Allowed Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 123.948 0.78 . . . . 2.7000000000000002 111.784 -177.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.594 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 13.9 Cg_exo -71.17 83.79 0.94 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.106 2.538 . . . . 1.49 114.357 -170.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.81 -22.04 44.33 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 110.721 -0.952 . . . . 1.1699999999999999 110.721 168.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.8 m120 74.68 92.2 0.08 Allowed 'General case' 0 N--CA 1.465 0.318 0 C-N-CA 123.749 0.82 . . . . 4.7199999999999998 111.915 174.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.487 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 59.7 m -143.05 -54.37 0.4 Allowed 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 116.055 -0.521 . . . . 2.98 111.943 174.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.559 ' HDA' ' O ' ' A' ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.46 -138.08 4.93 Favored Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.674 -0.694 . . . . 2.3399999999999999 111.545 -177.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -84.18 47.94 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.444 0.64 . . . . 2.6600000000000001 111.617 -177.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.594 ' CA ' ' HA ' ' A' ' 7' ' ' PRO . . . 152.14 -159.84 28.57 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.558 -0.829 . . . . 2.1000000000000001 112.734 177.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 51.1 t-80 . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.27 -0.872 . . . . 6.6299999999999999 111.15 -177.959 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 120.688 0.28 . . . . 2.4199999999999999 110.758 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -63.5 -51.04 67.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.049 0.452 . . . . 3.4700000000000002 110.048 178.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -78.5 135.9 37.46 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.801 -0.636 . . . . 2.5699999999999998 109.52 174.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.492 ' O ' ' HG ' ' A' ' 11' ' ' HZP . 35.8 p 53.01 99.71 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.415 1.086 . . . . 2.3100000000000001 113.542 170.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.408 ' O ' ' HB2' ' A' ' 10' ' ' SER . 41.2 p 47.4 82.53 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 115.621 -0.718 . . . . 2.7000000000000002 112.105 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -79.33 -158.53 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.812 2.341 . . . . 1.49 111.753 -178.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.63 56.89 5.74 Favored Glycine 0 N--CA 1.447 -0.627 0 C-N-CA 120.352 -0.928 . . . . 1.1699999999999999 111.903 -176.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 56.1 t30 50.88 64.94 1.63 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.18 0.514 . . . . 4.7199999999999998 111.283 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.557 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 46.1 m -130.72 -52.87 1.07 Allowed 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.303 -0.408 . . . . 2.98 111.087 175.577 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . 0.557 ' HD ' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.85 -85.39 1.51 Allowed Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.929 -0.653 . . . . 2.3399999999999999 111.978 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.8 m -83.59 47.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.407 0.622 . . . . 2.6600000000000001 111.702 -177.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.52 130.72 10.0 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.798 -0.715 . . . . 2.1000000000000001 111.944 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 . . . . . 0 C--O 1.247 0.921 0 CA-C-O 118.795 -0.622 . . . . 6.6299999999999999 109.777 -178.512 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.175 0 N-CA-C 109.92 -0.4 . . . . 2.4199999999999999 109.92 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -70.6 -31.72 68.81 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 108.646 -0.872 . . . . 3.4700000000000002 108.646 171.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -117.83 111.73 19.44 Favored 'General case' 0 N--CA 1.445 -0.685 0 N-CA-C 107.927 -1.138 . . . . 2.5699999999999998 107.927 168.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' HZP . . . . . 0.601 ' C ' ' HG1' ' A' ' 5' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.601 ' HG1' ' C ' ' A' ' 4' ' ' HZP . 17.0 p 51.85 32.36 9.65 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 124.298 1.039 . . . . 2.3100000000000001 111.966 -178.245 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.462 ' O ' HG21 ' A' ' 6' ' ' THR . 3.6 t 175.96 104.98 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 114.415 -1.266 . . . . 2.7000000000000002 108.546 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.475 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 8.7 Cg_endo -97.49 171.74 0.74 Allowed 'Trans proline' 0 CA--C 1.533 0.437 0 C-N-CA 123.702 2.935 . . . . 1.49 113.786 178.384 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.49 1.8 63.93 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.936 -0.574 . . . . 1.1699999999999999 113.637 172.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.1 p30 172.71 39.38 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 108.69 -0.856 . . . . 4.7199999999999998 108.69 -176.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.475 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.1 m -97.01 143.22 28.07 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.804 -1.089 . . . . 2.98 112.461 -164.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.79 -86.65 1.46 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.697 -0.763 . . . . 2.3399999999999999 112.196 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.35 -85.13 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 120.688 0.28 . . . . 2.6600000000000001 110.961 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.08 165.57 37.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.942 -0.647 . . . . 2.1000000000000001 112.493 -178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 . . . . . 0 C--O 1.246 0.902 0 CA-C-O 118.097 -0.954 . . . . 6.6299999999999999 110.321 179.106 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 120.754 0.311 . . . . 1.8500000000000001 110.977 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -73.81 -37.48 64.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.455 -0.339 . . . . 2.9700000000000002 111.468 -176.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.322 -0.606 0 N-CA-C 110.059 -0.349 . . . . 2.1200000000000001 110.059 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.1 p . . . . . 0 N--CA 1.469 0.486 0 N-CA-C 113.432 0.901 . . . . 2.1499999999999999 113.432 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -141.39 72.86 25.78 Favored Pre-proline 0 C--N 1.309 -1.156 0 CA-C-N 115.26 -0.882 . . . . 2.4300000000000002 110.498 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.45 162.12 43.17 Favored 'Trans proline' 0 C--O 1.234 0.288 0 C-N-CA 123.218 2.612 . . . . 1.23 112.238 -175.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.76 31.08 27.69 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.591 -0.814 . . . . 1.1699999999999999 112.228 -176.065 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.7 p30 41.01 42.43 1.53 Allowed 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.231 1.012 . . . . 3.96 113.039 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.4 m . . . . . 0 CA--C 1.539 0.553 0 CA-C-N 116.5 -0.318 . . . . 2.8599999999999999 111.421 178.78 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.458 0 N-CA-C 112.437 -0.265 . . . . 1.8100000000000001 112.437 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.12 133.33 53.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 110.047 -0.353 . . . . 2.0099999999999998 110.047 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.09 -173.4 43.55 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.918 -0.658 . . . . 2.1000000000000001 111.604 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 76.1 t60 . . . . . 0 C--O 1.242 0.699 0 CA-C-O 118.561 -0.733 . . . . 5.8600000000000003 109.76 179.252 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.132 0 CA-C-O 120.423 0.154 . . . . 1.8500000000000001 110.975 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -66.25 -41.3 90.13 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 121.195 0.521 . . . . 2.9700000000000002 110.33 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.595 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.689 0 CA-C-N 115.599 -0.728 . . . . 2.1200000000000001 109.395 175.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p . . . . . 0 N--CA 1.466 0.369 0 N-CA-C 112.539 0.57 . . . . 2.1499999999999999 112.539 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.7 p 45.5 68.5 3.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 113.044 0.757 . . . . 2.4300000000000002 113.044 178.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.48 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.9 Cg_exo -59.39 118.68 5.6 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.868 2.379 . . . . 1.23 111.914 177.283 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.3 -35.07 2.66 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.507 -0.769 . . . . 1.1699999999999999 111.196 -177.082 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.2 t30 -171.17 107.57 0.27 Allowed 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.962 -0.384 . . . . 3.96 109.962 177.649 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 21.9 p . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 2.8599999999999999 109.992 -179.052 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.503 0 N-CA-C 111.372 -0.691 . . . . 1.8100000000000001 111.372 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.646 HG13 ' H ' ' A' ' 14' ' ' GLY . 2.7 p -166.78 -65.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 110.063 -0.347 . . . . 2.0099999999999998 110.063 175.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.646 ' H ' HG13 ' A' ' 13' ' ' VAL . . . 78.29 130.63 0.59 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.779 -0.724 . . . . 2.1000000000000001 112.689 177.209 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 . . . . . 0 C--O 1.246 0.873 0 CA-C-O 118.597 -0.716 . . . . 5.8600000000000003 109.849 -178.127 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.121 0 CA-C-O 120.684 0.278 . . . . 1.8500000000000001 110.49 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -69.38 -38.74 78.15 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 121.775 0.797 . . . . 2.9700000000000002 109.138 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.582 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.2 OUTLIER . . . . . 0 N--CA 1.443 -0.819 0 CA-C-N 114.254 -1.339 . . . . 2.1200000000000001 109.384 177.104 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 66.8 p . . . . . 0 N--CA 1.467 0.415 0 N-CA-C 112.679 0.622 . . . . 2.1499999999999999 112.679 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 t -48.49 113.47 2.92 Favored Pre-proline 0 CA--C 1.535 0.402 0 C-N-CA 123.352 0.661 . . . . 2.4300000000000002 112.316 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.57 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 69.2 Cg_exo -57.5 156.63 25.7 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 123.342 2.695 . . . . 1.23 113.094 176.358 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.95 -39.58 2.7 Favored Glycine 0 N--CA 1.447 -0.626 0 CA-C-N 115.425 -0.807 . . . . 1.1699999999999999 111.885 -177.094 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -133.29 24.96 4.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.529 0.681 . . . . 3.96 109.914 -177.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.57 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.3 m . . . . . 0 C--N 1.321 -0.649 0 CA-C-N 115.271 -0.877 . . . . 2.8599999999999999 111.191 -176.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.393 0 N-CA-C 112.374 -0.29 . . . . 1.8100000000000001 112.374 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.5 t -97.32 -68.4 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 110.22 -0.289 . . . . 2.0099999999999998 110.22 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.68 49.36 56.04 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.716 -0.754 . . . . 2.1000000000000001 113.131 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 t60 . . . . . 0 C--O 1.244 0.796 0 CA-C-O 118.474 -0.774 . . . . 5.8600000000000003 109.943 177.245 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.652 0.263 . . . . 1.8500000000000001 110.802 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -129.56 25.2 5.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.349 0.595 . . . . 2.9700000000000002 109.879 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 13.3 pm0 . . . . . 0 C--N 1.322 -0.627 0 CA-C-N 115.56 -0.746 . . . . 2.1200000000000001 109.629 -179.89 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.8 p . . . . . 0 N--CA 1.469 0.495 0 CA-C-O 121.354 0.597 . . . . 2.1499999999999999 111.994 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 4.3 t 176.05 103.56 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.99 -1.004 . . . . 2.4300000000000002 110.086 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -81.45 -171.42 1.21 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.859 2.373 . . . . 1.23 112.149 175.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 90.09 -1.45 80.22 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 121.019 -0.61 . . . . 1.1699999999999999 112.714 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.2 t30 60.66 71.76 0.55 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.232 0.539 . . . . 3.96 110.597 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.0 m . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.0 -0.546 . . . . 2.8599999999999999 111.631 179.55 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.59 0 N-CA-C 112.279 -0.329 . . . . 1.8100000000000001 112.279 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.61 163.88 17.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 110.087 -0.338 . . . . 2.0099999999999998 110.087 -179.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.92 152.48 5.65 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.426 -0.67 . . . . 2.1000000000000001 111.426 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.672 -0.68 . . . . 5.8600000000000003 109.825 -178.215 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.039 0 CA-C-O 120.579 0.228 . . . . 1.8500000000000001 110.967 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.58 -72.4 0.71 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.128 0.489 . . . . 2.9700000000000002 109.884 179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.566 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.446 -0.636 0 CA-C-N 115.649 -0.705 . . . . 2.1200000000000001 109.48 175.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.6 p . . . . . 0 N--CA 1.469 0.5 0 N-CA-C 111.739 0.274 . . . . 2.1499999999999999 111.739 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.5 p -50.7 123.76 18.59 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.317 -0.401 . . . . 2.4300000000000002 112.05 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.537 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.8 Cg_exo -56.14 156.72 19.51 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.063 2.509 . . . . 1.23 112.517 176.229 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 95.5 82.74 1.61 Allowed Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 111.408 -0.677 . . . . 1.1699999999999999 111.408 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 69.19 42.83 1.17 Allowed 'General case' 0 CA--C 1.52 -0.188 0 CA-C-O 121.566 0.698 . . . . 3.96 109.752 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.627 ' OG ' ' HA3' ' A' ' 14' ' ' GLY . 4.4 m . . . . . 0 C--N 1.322 -0.622 0 CA-C-N 114.988 -1.006 . . . . 2.8599999999999999 110.42 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.634 0 N-CA-C 111.349 -0.701 . . . . 1.8100000000000001 111.349 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.5 p -165.36 122.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.073 0.463 . . . . 2.0099999999999998 110.497 177.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.627 ' HA3' ' OG ' ' A' ' 10' ' ' SER . . . -159.95 135.03 3.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.579 -0.82 . . . . 2.1000000000000001 112.885 -178.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 69.6 m80 . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.353 -0.832 . . . . 5.8600000000000003 109.838 177.958 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.986 0 N-CA-C 110.557 -0.164 . . . . 1.8500000000000001 110.557 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 67.67 -75.82 0.06 Allowed 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 123.679 0.792 . . . . 2.9700000000000002 111.258 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 116.439 -0.346 . . . . 2.1200000000000001 110.345 179.14 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.8 p . . . . . 0 N--CA 1.467 0.392 0 N-CA-C 112.737 0.643 . . . . 2.1499999999999999 112.737 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.487 HG23 ' HB3' ' A' ' 10' ' ' SER . 3.7 t 36.85 65.37 2.35 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 124.377 1.071 . . . . 2.4300000000000002 113.203 179.18 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -59.2 132.37 46.45 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.727 2.285 . . . . 1.23 111.718 175.466 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.452 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 122.14 -47.17 1.04 Allowed Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.265 -1.134 . . . . 1.1699999999999999 110.265 -171.175 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -164.67 105.8 0.84 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.894 -0.41 . . . . 3.96 109.894 175.613 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.487 ' HB3' HG23 ' A' ' 6' ' ' THR . 86.8 p . . . . . 0 C--N 1.322 -0.617 0 N-CA-C 108.798 -0.816 . . . . 2.8599999999999999 108.798 176.1 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.441 0 N-CA-C 111.838 -0.505 . . . . 1.8100000000000001 111.838 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.1 t -135.69 -86.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 2.0099999999999998 110.157 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.452 ' C ' ' H ' ' A' ' 8' ' ' GLY . . . 82.3 109.99 0.43 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.79 -0.719 . . . . 2.1000000000000001 111.892 -177.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 4.0 p80 . . . . . 0 C--O 1.245 0.816 0 CA-C-O 118.378 -0.82 . . . . 5.8600000000000003 109.873 -179.636 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.182 0 CA-C-O 120.438 0.161 . . . . 1.8500000000000001 110.919 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -66.69 -53.43 33.7 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.043 0.449 . . . . 2.9700000000000002 110.364 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.496 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 5.1 pm0 . . . . . 0 N--CA 1.445 -0.681 0 CA-C-N 115.9 -0.591 . . . . 2.1200000000000001 109.785 176.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p . . . . . 0 N--CA 1.465 0.312 0 N-CA-C 110.547 -0.168 . . . . 2.1499999999999999 110.547 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.468 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 2.9 t -41.3 109.95 0.7 Allowed Pre-proline 0 CA--C 1.539 0.554 0 O-C-N 123.602 0.564 . . . . 2.4300000000000002 111.763 177.624 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.491 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 2.7 Cg_exo -75.98 -166.96 0.4 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.937 2.425 . . . . 1.23 112.79 -177.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.0 24.17 62.3 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.98 -0.628 . . . . 1.1699999999999999 111.696 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 62.12 28.35 17.08 Favored 'General case' 0 C--N 1.333 -0.151 0 C-N-CA 122.748 0.419 . . . . 3.96 111.372 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.9 m . . . . . 0 CA--C 1.537 0.472 0 CA-C-N 116.356 -0.384 . . . . 2.8599999999999999 111.404 179.21 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 N-CA-C 111.826 -0.51 . . . . 1.8100000000000001 111.826 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.3 p -138.35 166.43 23.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.969 -0.382 . . . . 2.0099999999999998 109.969 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.15 159.16 10.16 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.034 -0.603 . . . . 2.1000000000000001 112.002 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 7.9 p80 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.454 -0.784 . . . . 5.8600000000000003 110.269 -178.072 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.06 0 N-CA-C 110.094 -0.336 . . . . 1.8500000000000001 110.094 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -61.75 -29.44 70.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.735 0.302 . . . . 2.9700000000000002 110.936 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 . . . . . 0 C--N 1.325 -0.498 0 N-CA-C 109.765 -0.457 . . . . 2.1200000000000001 109.765 175.127 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 43.6 p . . . . . 0 N--CA 1.468 0.461 0 N-CA-C 112.155 0.428 . . . . 2.1499999999999999 112.155 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.499 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 4.5 t -40.42 105.85 0.39 Allowed Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 123.948 0.78 . . . . 2.4300000000000002 111.784 -177.531 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.577 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 13.9 Cg_exo -71.17 83.79 0.94 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.106 2.538 . . . . 1.23 114.357 -170.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.81 -22.04 44.33 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 110.721 -0.952 . . . . 1.1699999999999999 110.721 168.366 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.8 m120 74.68 92.2 0.08 Allowed 'General case' 0 N--CA 1.465 0.318 0 C-N-CA 123.749 0.82 . . . . 3.96 111.915 174.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 59.7 m . . . . . 0 CA--C 1.541 0.608 0 CA-C-N 116.055 -0.521 . . . . 2.8599999999999999 111.943 174.798 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.643 0 N-CA-C 111.545 -0.622 . . . . 1.8100000000000001 111.545 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -84.18 47.94 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.444 0.64 . . . . 2.0099999999999998 111.617 -177.691 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.577 ' CA ' ' HA ' ' A' ' 7' ' ' PRO . . . 152.14 -159.84 28.57 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.558 -0.829 . . . . 2.1000000000000001 112.734 177.161 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 51.1 t-80 . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.27 -0.872 . . . . 5.8600000000000003 111.15 -177.959 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 120.688 0.28 . . . . 1.8500000000000001 110.758 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -63.5 -51.04 67.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.049 0.452 . . . . 2.9700000000000002 110.048 178.656 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 . . . . . 0 C--N 1.325 -0.476 0 CA-C-N 115.801 -0.636 . . . . 2.1200000000000001 109.52 174.781 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 35.8 p . . . . . 0 N--CA 1.468 0.471 0 N-CA-C 113.542 0.941 . . . . 2.1499999999999999 113.542 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 10' ' ' SER . 41.2 p 47.4 82.53 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 115.621 -0.718 . . . . 2.4300000000000002 112.105 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -79.33 -158.53 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.812 2.341 . . . . 1.23 111.753 -178.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.63 56.89 5.74 Favored Glycine 0 N--CA 1.447 -0.627 0 C-N-CA 120.352 -0.928 . . . . 1.1699999999999999 111.903 -176.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 56.1 t30 50.88 64.94 1.63 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.18 0.514 . . . . 3.96 111.283 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.416 ' HB2' ' O ' ' A' ' 6' ' ' THR . 46.1 m . . . . . 0 C--N 1.322 -0.601 0 CA-C-N 116.303 -0.408 . . . . 2.8599999999999999 111.087 175.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.547 0 N-CA-C 111.978 -0.449 . . . . 1.8100000000000001 111.978 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.8 m -83.59 47.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.407 0.622 . . . . 2.0099999999999998 111.702 -177.16 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.52 130.72 10.0 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.798 -0.715 . . . . 2.1000000000000001 111.944 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 . . . . . 0 C--O 1.247 0.921 0 CA-C-O 118.795 -0.622 . . . . 5.8600000000000003 109.777 -178.512 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.175 0 N-CA-C 109.92 -0.4 . . . . 1.8500000000000001 109.92 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -70.6 -31.72 68.81 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 108.646 -0.872 . . . . 2.9700000000000002 108.646 171.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 . . . . . 0 N--CA 1.445 -0.685 0 N-CA-C 107.927 -1.138 . . . . 2.1200000000000001 107.927 168.889 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.0 p . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 121.676 0.751 . . . . 2.1499999999999999 111.966 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.6 t 175.96 104.98 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 114.415 -1.266 . . . . 2.4300000000000002 108.546 176.092 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.558 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 8.7 Cg_endo -97.49 171.74 0.74 Allowed 'Trans proline' 0 CA--C 1.533 0.437 0 C-N-CA 123.702 2.935 . . . . 1.23 113.786 178.384 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.49 1.8 63.93 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.936 -0.574 . . . . 1.1699999999999999 113.637 172.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.1 p30 172.71 39.38 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 108.69 -0.856 . . . . 3.96 108.69 -176.034 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.558 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.1 m . . . . . 0 C--N 1.312 -1.044 0 CA-C-N 114.804 -1.089 . . . . 2.8599999999999999 112.461 -164.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.542 0 N-CA-C 112.196 -0.361 . . . . 1.8100000000000001 112.196 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.35 -85.13 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 120.688 0.28 . . . . 2.0099999999999998 110.961 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.08 165.57 37.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.942 -0.647 . . . . 2.1000000000000001 112.493 -178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 . . . . . 0 C--O 1.246 0.902 0 CA-C-O 118.097 -0.954 . . . . 5.8600000000000003 110.321 179.106 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 120.754 0.311 . . . . 1.8500000000000001 110.977 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -73.81 -37.48 64.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.455 -0.339 . . . . 2.9700000000000002 111.468 -176.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.416 ' C ' ' H ' ' A' ' 5' ' ' THR . 0.6 OUTLIER -87.42 134.46 33.59 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.059 -0.349 . . . . 2.1200000000000001 110.059 178.804 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.416 ' H ' ' C ' ' A' ' 3' ' ' GLN . 82.1 p 53.13 17.15 0.9 Allowed 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 125.087 1.355 . . . . 2.1499999999999999 113.432 177.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -141.39 72.86 25.78 Favored Pre-proline 0 C--N 1.309 -1.156 0 CA-C-N 115.26 -0.882 . . . . 2.4300000000000002 110.498 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.45 162.12 43.17 Favored 'Trans proline' 0 C--O 1.234 0.288 0 C-N-CA 123.218 2.612 . . . . 1.23 112.238 -175.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.76 31.08 27.69 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.591 -0.814 . . . . 1.1699999999999999 112.228 -176.065 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.7 p30 41.01 42.43 1.53 Allowed 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.231 1.012 . . . . 3.96 113.039 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.516 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 14.4 m -61.66 -47.37 85.65 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 116.5 -0.318 . . . . 2.8599999999999999 111.421 178.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.516 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.84 -49.22 1.28 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.965 -0.636 . . . . 1.8100000000000001 112.437 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.12 133.33 53.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 110.047 -0.353 . . . . 2.0099999999999998 110.047 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.09 -173.4 43.55 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.918 -0.658 . . . . 2.1000000000000001 111.604 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 76.1 t60 . . . . . 0 C--O 1.242 0.699 0 CA-C-O 118.561 -0.733 . . . . 5.8600000000000003 109.76 179.252 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.132 0 CA-C-O 120.423 0.154 . . . . 1.8500000000000001 110.975 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -66.25 -41.3 90.13 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 121.195 0.521 . . . . 2.9700000000000002 110.33 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.595 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER -91.57 124.46 35.74 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.599 -0.728 . . . . 2.1200000000000001 109.395 175.843 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p 60.56 163.92 0.07 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 124.632 1.173 . . . . 2.1499999999999999 112.539 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.7 p 45.5 68.5 3.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 113.044 0.757 . . . . 2.4300000000000002 113.044 178.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.48 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.9 Cg_exo -59.39 118.68 5.6 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.868 2.379 . . . . 1.23 111.914 177.283 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.3 -35.07 2.66 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.507 -0.769 . . . . 1.1699999999999999 111.196 -177.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.2 t30 -171.17 107.57 0.27 Allowed 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.962 -0.384 . . . . 3.96 109.962 177.649 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.455 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 21.9 p -141.78 167.15 22.84 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 2.8599999999999999 109.992 -179.052 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.455 ' HD ' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.26 -67.97 1.78 Allowed Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.63 -0.795 . . . . 1.8100000000000001 111.372 176.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.646 HG13 ' H ' ' A' ' 14' ' ' GLY . 2.7 p -166.78 -65.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 110.063 -0.347 . . . . 2.0099999999999998 110.063 175.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.646 ' H ' HG13 ' A' ' 13' ' ' VAL . . . 78.29 130.63 0.59 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.779 -0.724 . . . . 2.1000000000000001 112.689 177.209 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 . . . . . 0 C--O 1.246 0.873 0 CA-C-O 118.597 -0.716 . . . . 5.8600000000000003 109.849 -178.127 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.121 0 CA-C-O 120.684 0.278 . . . . 1.8500000000000001 110.49 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -69.38 -38.74 78.15 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 121.775 0.797 . . . . 2.9700000000000002 109.138 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.582 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.2 OUTLIER -96.33 157.18 16.02 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-N 114.254 -1.339 . . . . 2.1200000000000001 109.384 177.104 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.54 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 66.8 p 60.66 -173.18 0.13 Allowed 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 124.791 1.236 . . . . 2.1499999999999999 112.679 178.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 t -48.49 113.47 2.92 Favored Pre-proline 0 CA--C 1.535 0.402 0 C-N-CA 123.352 0.661 . . . . 2.4300000000000002 112.316 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.57 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 69.2 Cg_exo -57.5 156.63 25.7 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 123.342 2.695 . . . . 1.23 113.094 176.358 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.95 -39.58 2.7 Favored Glycine 0 N--CA 1.447 -0.626 0 CA-C-N 115.425 -0.807 . . . . 1.1699999999999999 111.885 -177.094 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -133.29 24.96 4.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.529 0.681 . . . . 3.96 109.914 -177.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.57 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.3 m -76.58 149.46 36.61 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.271 -0.877 . . . . 2.8599999999999999 111.191 -176.234 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.32 -66.15 0.28 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.737 -0.744 . . . . 1.8100000000000001 112.374 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.5 t -97.32 -68.4 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 110.22 -0.289 . . . . 2.0099999999999998 110.22 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.68 49.36 56.04 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.716 -0.754 . . . . 2.1000000000000001 113.131 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 t60 . . . . . 0 C--O 1.244 0.796 0 CA-C-O 118.474 -0.774 . . . . 5.8600000000000003 109.943 177.245 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.652 0.263 . . . . 1.8500000000000001 110.802 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -129.56 25.2 5.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.349 0.595 . . . . 2.9700000000000002 109.879 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 13.3 pm0 -130.58 147.01 52.21 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.56 -0.746 . . . . 2.1200000000000001 109.629 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.412 ' O ' HG22 ' A' ' 6' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.8 p 56.33 28.13 12.96 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.393 1.077 . . . . 2.1499999999999999 111.994 -178.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.412 HG22 ' O ' ' A' ' 4' ' ' HZP . 4.3 t 176.05 103.56 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.99 -1.004 . . . . 2.4300000000000002 110.086 178.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -81.45 -171.42 1.21 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.859 2.373 . . . . 1.23 112.149 175.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 90.09 -1.45 80.22 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 121.019 -0.61 . . . . 1.1699999999999999 112.714 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.2 t30 60.66 71.76 0.55 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.232 0.539 . . . . 3.96 110.597 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.54 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 19.0 m -114.57 -53.24 2.67 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.0 -0.546 . . . . 2.8599999999999999 111.631 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.54 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.83 -58.86 0.57 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.869 -0.682 . . . . 1.8100000000000001 112.279 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.61 163.88 17.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 110.087 -0.338 . . . . 2.0099999999999998 110.087 -179.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.92 152.48 5.65 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.426 -0.67 . . . . 2.1000000000000001 111.426 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.672 -0.68 . . . . 5.8600000000000003 109.825 -178.215 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.039 0 CA-C-O 120.579 0.228 . . . . 1.8500000000000001 110.967 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.58 -72.4 0.71 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.128 0.489 . . . . 2.9700000000000002 109.884 179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.566 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER -97.11 146.05 25.41 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.649 -0.705 . . . . 2.1200000000000001 109.48 175.989 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.466 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.6 p 70.06 -171.04 0.17 Allowed 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 125.18 1.392 . . . . 2.1499999999999999 111.739 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.5 p -50.7 123.76 18.59 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.317 -0.401 . . . . 2.4300000000000002 112.05 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.537 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.8 Cg_exo -56.14 156.72 19.51 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.063 2.509 . . . . 1.23 112.517 176.229 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 95.5 82.74 1.61 Allowed Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 111.408 -0.677 . . . . 1.1699999999999999 111.408 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 69.19 42.83 1.17 Allowed 'General case' 0 CA--C 1.52 -0.188 0 CA-C-O 121.566 0.698 . . . . 3.96 109.752 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.627 ' OG ' ' HA3' ' A' ' 14' ' ' GLY . 4.4 m -76.53 148.27 37.21 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.988 -1.006 . . . . 2.8599999999999999 110.42 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 123.63 -70.87 0.44 Allowed Glycine 0 N--CA 1.446 -0.634 0 N-CA-C 111.349 -0.701 . . . . 1.8100000000000001 111.349 -176.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.5 p -165.36 122.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.073 0.463 . . . . 2.0099999999999998 110.497 177.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.627 ' HA3' ' OG ' ' A' ' 10' ' ' SER . . . -159.95 135.03 3.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.579 -0.82 . . . . 2.1000000000000001 112.885 -178.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 69.6 m80 . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.353 -0.832 . . . . 5.8600000000000003 109.838 177.958 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.986 0 N-CA-C 110.557 -0.164 . . . . 1.8500000000000001 110.557 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 67.67 -75.82 0.06 Allowed 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 123.679 0.792 . . . . 2.9700000000000002 111.258 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -80.09 126.33 30.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.439 -0.346 . . . . 2.1200000000000001 110.345 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.8 p 57.78 -175.22 0.08 Allowed 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.445 1.098 . . . . 2.1499999999999999 112.737 176.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.487 HG23 ' HB3' ' A' ' 10' ' ' SER . 3.7 t 36.85 65.37 2.35 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 124.377 1.071 . . . . 2.4300000000000002 113.203 179.18 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -59.2 132.37 46.45 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.727 2.285 . . . . 1.23 111.718 175.466 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.452 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 122.14 -47.17 1.04 Allowed Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.265 -1.134 . . . . 1.1699999999999999 110.265 -171.175 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -164.67 105.8 0.84 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.894 -0.41 . . . . 3.96 109.894 175.613 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.487 ' HB3' HG23 ' A' ' 6' ' ' THR . 86.8 p -131.04 158.97 38.9 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.798 -0.816 . . . . 2.8599999999999999 108.798 176.1 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.63 -74.48 0.69 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.819 -0.705 . . . . 1.8100000000000001 111.838 177.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.1 t -135.69 -86.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 2.0099999999999998 110.157 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.452 ' C ' ' H ' ' A' ' 8' ' ' GLY . . . 82.3 109.99 0.43 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.79 -0.719 . . . . 2.1000000000000001 111.892 -177.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 4.0 p80 . . . . . 0 C--O 1.245 0.816 0 CA-C-O 118.378 -0.82 . . . . 5.8600000000000003 109.873 -179.636 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.182 0 CA-C-O 120.438 0.161 . . . . 1.8500000000000001 110.919 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -66.69 -53.43 33.7 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.043 0.449 . . . . 2.9700000000000002 110.364 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.496 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 5.1 pm0 -84.3 141.44 30.93 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-N 115.9 -0.591 . . . . 2.1200000000000001 109.785 176.642 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p 55.34 -161.83 0.16 Allowed 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 123.602 0.761 . . . . 2.1499999999999999 110.547 -175.127 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.506 ' O ' ' HDA' ' A' ' 11' ' ' HZP . 2.9 t -41.3 109.95 0.7 Allowed Pre-proline 0 CA--C 1.539 0.554 0 O-C-N 123.602 0.564 . . . . 2.4300000000000002 111.763 177.624 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.491 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 2.7 Cg_exo -75.98 -166.96 0.4 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.937 2.425 . . . . 1.23 112.79 -177.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.0 24.17 62.3 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.98 -0.628 . . . . 1.1699999999999999 111.696 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 62.12 28.35 17.08 Favored 'General case' 0 C--N 1.333 -0.151 0 C-N-CA 122.748 0.419 . . . . 3.96 111.372 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.507 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 15.9 m -65.75 -48.86 70.47 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.356 -0.384 . . . . 2.8599999999999999 111.404 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.507 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 118.6 -38.1 3.0 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.401 -0.818 . . . . 1.8100000000000001 111.826 -179.015 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.3 p -138.35 166.43 23.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.969 -0.382 . . . . 2.0099999999999998 109.969 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.15 159.16 10.16 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.034 -0.603 . . . . 2.1000000000000001 112.002 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 7.9 p80 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.454 -0.784 . . . . 5.8600000000000003 110.269 -178.072 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.06 0 N-CA-C 110.094 -0.336 . . . . 1.8500000000000001 110.094 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -61.75 -29.44 70.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.735 0.302 . . . . 2.9700000000000002 110.936 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 -102.79 141.99 34.67 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.765 -0.457 . . . . 2.1200000000000001 109.765 175.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 43.6 p 67.56 -171.8 0.19 Allowed 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 124.438 1.095 . . . . 2.1499999999999999 112.155 171.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.499 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 4.5 t -40.42 105.85 0.39 Allowed Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 123.948 0.78 . . . . 2.4300000000000002 111.784 -177.531 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.577 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 13.9 Cg_exo -71.17 83.79 0.94 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.106 2.538 . . . . 1.23 114.357 -170.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.81 -22.04 44.33 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 110.721 -0.952 . . . . 1.1699999999999999 110.721 168.366 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.8 m120 74.68 92.2 0.08 Allowed 'General case' 0 N--CA 1.465 0.318 0 C-N-CA 123.749 0.82 . . . . 3.96 111.915 174.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.537 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 59.7 m -143.05 -54.37 0.4 Allowed 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 116.055 -0.521 . . . . 2.8599999999999999 111.943 174.798 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.573 ' HD ' ' O ' ' A' ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.46 -138.08 4.93 Favored Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.674 -0.694 . . . . 1.8100000000000001 111.545 -177.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -84.18 47.94 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.444 0.64 . . . . 2.0099999999999998 111.617 -177.691 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.577 ' CA ' ' HA ' ' A' ' 7' ' ' PRO . . . 152.14 -159.84 28.57 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.558 -0.829 . . . . 2.1000000000000001 112.734 177.161 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 51.1 t-80 . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.27 -0.872 . . . . 5.8600000000000003 111.15 -177.959 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 120.688 0.28 . . . . 1.8500000000000001 110.758 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -63.5 -51.04 67.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.049 0.452 . . . . 2.9700000000000002 110.048 178.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -78.5 135.9 37.46 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.801 -0.636 . . . . 2.1200000000000001 109.52 174.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.492 ' O ' ' HG ' ' A' ' 11' ' ' HZP . 35.8 p 53.01 99.71 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.415 1.086 . . . . 2.1499999999999999 113.542 170.517 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 10' ' ' SER . 41.2 p 47.4 82.53 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 115.621 -0.718 . . . . 2.4300000000000002 112.105 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -79.33 -158.53 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.812 2.341 . . . . 1.23 111.753 -178.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.63 56.89 5.74 Favored Glycine 0 N--CA 1.447 -0.627 0 C-N-CA 120.352 -0.928 . . . . 1.1699999999999999 111.903 -176.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 56.1 t30 50.88 64.94 1.63 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.18 0.514 . . . . 3.96 111.283 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.577 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 46.1 m -130.72 -52.87 1.07 Allowed 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.303 -0.408 . . . . 2.8599999999999999 111.087 175.577 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' HZP . . . . . 0.577 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.85 -85.39 1.51 Allowed Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.929 -0.653 . . . . 1.8100000000000001 111.978 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.8 m -83.59 47.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.407 0.622 . . . . 2.0099999999999998 111.702 -177.16 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.52 130.72 10.0 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.798 -0.715 . . . . 2.1000000000000001 111.944 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 . . . . . 0 C--O 1.247 0.921 0 CA-C-O 118.795 -0.622 . . . . 5.8600000000000003 109.777 -178.512 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.175 0 N-CA-C 109.92 -0.4 . . . . 1.8500000000000001 109.92 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -70.6 -31.72 68.81 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 108.646 -0.872 . . . . 2.9700000000000002 108.646 171.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -117.83 111.73 19.44 Favored 'General case' 0 N--CA 1.445 -0.685 0 N-CA-C 107.927 -1.138 . . . . 2.1200000000000001 107.927 168.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' HZP . . . . . 0.436 ' OD1' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.0 p 51.85 32.36 9.65 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 124.298 1.039 . . . . 2.1499999999999999 111.966 -178.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.433 HG22 ' O ' ' A' ' 4' ' ' HZP . 3.6 t 175.96 104.98 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 114.415 -1.266 . . . . 2.4300000000000002 108.546 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.558 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 8.7 Cg_endo -97.49 171.74 0.74 Allowed 'Trans proline' 0 CA--C 1.533 0.437 0 C-N-CA 123.702 2.935 . . . . 1.23 113.786 178.384 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.49 1.8 63.93 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.936 -0.574 . . . . 1.1699999999999999 113.637 172.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.1 p30 172.71 39.38 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 108.69 -0.856 . . . . 3.96 108.69 -176.034 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.558 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.1 m -97.01 143.22 28.07 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.804 -1.089 . . . . 2.8599999999999999 112.461 -164.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.79 -86.65 1.46 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.697 -0.763 . . . . 1.8100000000000001 112.196 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.35 -85.13 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 120.688 0.28 . . . . 2.0099999999999998 110.961 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.08 165.57 37.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.942 -0.647 . . . . 2.1000000000000001 112.493 -178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 . . . . . 0 C--O 1.246 0.902 0 CA-C-O 118.097 -0.954 . . . . 5.8600000000000003 110.321 179.106 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 120.754 0.311 . . . . 1.85 110.977 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -73.81 -37.48 64.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.455 -0.339 . . . . 2.97 111.468 -176.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.322 -0.606 0 N-CA-C 110.059 -0.349 . . . . 2.12 110.059 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.1 p . . . . . 0 N--CA 1.469 0.486 0 N-CA-C 113.432 0.901 . . . . 2.15 113.432 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -141.39 72.86 25.78 Favored Pre-proline 0 C--N 1.309 -1.156 0 CA-C-N 115.26 -0.882 . . . . 2.43 110.498 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.45 162.12 43.17 Favored 'Trans proline' 0 C--O 1.234 0.288 0 C-N-CA 123.218 2.612 . . . . 1.23 112.238 -175.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.76 31.08 27.69 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.591 -0.814 . . . . 1.17 112.228 -176.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.7 p30 41.01 42.43 1.53 Allowed 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.231 1.012 . . . . 3.96 113.039 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.4 m . . . . . 0 CA--C 1.539 0.553 0 CA-C-N 116.5 -0.318 . . . . 2.86 111.421 178.78 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.458 0 N-CA-C 112.437 -0.265 . . . . 1.81 112.437 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.12 133.33 53.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 110.047 -0.353 . . . . 2.01 110.047 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.09 -173.4 43.55 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.918 -0.658 . . . . 2.1 111.604 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 76.1 t60 . . . . . 0 C--O 1.242 0.699 0 CA-C-O 118.561 -0.733 . . . . 5.86 109.76 179.252 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.132 0 CA-C-O 120.423 0.154 . . . . 1.85 110.975 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -66.25 -41.3 90.13 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 121.195 0.521 . . . . 2.97 110.33 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.595 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.689 0 CA-C-N 115.599 -0.728 . . . . 2.12 109.395 175.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p . . . . . 0 N--CA 1.466 0.369 0 N-CA-C 112.539 0.57 . . . . 2.15 112.539 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.7 p 45.5 68.5 3.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 113.044 0.757 . . . . 2.43 113.044 178.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.48 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.9 Cg_exo -59.39 118.68 5.6 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.868 2.379 . . . . 1.23 111.914 177.283 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.3 -35.07 2.66 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.507 -0.769 . . . . 1.17 111.196 -177.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.2 t30 -171.17 107.57 0.27 Allowed 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.962 -0.384 . . . . 3.96 109.962 177.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 21.9 p . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 2.86 109.992 -179.052 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.503 0 N-CA-C 111.372 -0.691 . . . . 1.81 111.372 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.646 HG13 ' H ' ' A' ' 14' ' ' GLY . 2.7 p -166.78 -65.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 110.063 -0.347 . . . . 2.01 110.063 175.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.646 ' H ' HG13 ' A' ' 13' ' ' VAL . . . 78.29 130.63 0.59 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.779 -0.724 . . . . 2.1 112.689 177.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 . . . . . 0 C--O 1.246 0.873 0 CA-C-O 118.597 -0.716 . . . . 5.86 109.849 -178.127 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.121 0 CA-C-O 120.684 0.278 . . . . 1.85 110.49 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -69.38 -38.74 78.15 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 121.775 0.797 . . . . 2.97 109.138 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.582 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.2 OUTLIER . . . . . 0 N--CA 1.443 -0.819 0 CA-C-N 114.254 -1.339 . . . . 2.12 109.384 177.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 66.8 p . . . . . 0 N--CA 1.467 0.415 0 N-CA-C 112.679 0.622 . . . . 2.15 112.679 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 t -48.49 113.47 2.92 Favored Pre-proline 0 CA--C 1.535 0.402 0 C-N-CA 123.352 0.661 . . . . 2.43 112.316 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.57 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 69.2 Cg_exo -57.5 156.63 25.7 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 123.342 2.695 . . . . 1.23 113.094 176.358 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.95 -39.58 2.7 Favored Glycine 0 N--CA 1.447 -0.626 0 CA-C-N 115.425 -0.807 . . . . 1.17 111.885 -177.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -133.29 24.96 4.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.529 0.681 . . . . 3.96 109.914 -177.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.57 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.3 m . . . . . 0 C--N 1.321 -0.649 0 CA-C-N 115.271 -0.877 . . . . 2.86 111.191 -176.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.393 0 N-CA-C 112.374 -0.29 . . . . 1.81 112.374 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.5 t -97.32 -68.4 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 110.22 -0.289 . . . . 2.01 110.22 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.68 49.36 56.04 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.716 -0.754 . . . . 2.1 113.131 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 t60 . . . . . 0 C--O 1.244 0.796 0 CA-C-O 118.474 -0.774 . . . . 5.86 109.943 177.245 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.652 0.263 . . . . 1.85 110.802 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -129.56 25.2 5.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.349 0.595 . . . . 2.97 109.879 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 13.3 pm0 . . . . . 0 C--N 1.322 -0.627 0 CA-C-N 115.56 -0.746 . . . . 2.12 109.629 -179.89 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.8 p . . . . . 0 N--CA 1.469 0.495 0 CA-C-O 121.354 0.597 . . . . 2.15 111.994 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 4.3 t 176.05 103.56 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.99 -1.004 . . . . 2.43 110.086 178.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -81.45 -171.42 1.21 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.859 2.373 . . . . 1.23 112.149 175.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 90.09 -1.45 80.22 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 121.019 -0.61 . . . . 1.17 112.714 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 60.66 71.76 0.55 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.232 0.539 . . . . 3.96 110.597 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.0 m . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.0 -0.546 . . . . 2.86 111.631 179.55 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.59 0 N-CA-C 112.279 -0.329 . . . . 1.81 112.279 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.61 163.88 17.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 110.087 -0.338 . . . . 2.01 110.087 -179.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.92 152.48 5.65 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.426 -0.67 . . . . 2.1 111.426 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.672 -0.68 . . . . 5.86 109.825 -178.215 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.039 0 CA-C-O 120.579 0.228 . . . . 1.85 110.967 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.58 -72.4 0.71 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.128 0.489 . . . . 2.97 109.884 179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.566 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.446 -0.636 0 CA-C-N 115.649 -0.705 . . . . 2.12 109.48 175.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.6 p . . . . . 0 N--CA 1.469 0.5 0 N-CA-C 111.739 0.274 . . . . 2.15 111.739 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.5 p -50.7 123.76 18.59 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.317 -0.401 . . . . 2.43 112.05 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.537 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.8 Cg_exo -56.14 156.72 19.51 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.063 2.509 . . . . 1.23 112.517 176.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 95.5 82.74 1.61 Allowed Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 111.408 -0.677 . . . . 1.17 111.408 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 69.19 42.83 1.17 Allowed 'General case' 0 CA--C 1.52 -0.188 0 CA-C-O 121.566 0.698 . . . . 3.96 109.752 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.627 ' OG ' ' HA3' ' A' ' 14' ' ' GLY . 4.4 m . . . . . 0 C--N 1.322 -0.622 0 CA-C-N 114.988 -1.006 . . . . 2.86 110.42 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.634 0 N-CA-C 111.349 -0.701 . . . . 1.81 111.349 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.5 p -165.36 122.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.073 0.463 . . . . 2.01 110.497 177.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.627 ' HA3' ' OG ' ' A' ' 10' ' ' SER . . . -159.95 135.03 3.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.579 -0.82 . . . . 2.1 112.885 -178.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 69.6 m80 . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.353 -0.832 . . . . 5.86 109.838 177.958 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.986 0 N-CA-C 110.557 -0.164 . . . . 1.85 110.557 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 67.67 -75.82 0.06 Allowed 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 123.679 0.792 . . . . 2.97 111.258 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 116.439 -0.346 . . . . 2.12 110.345 179.14 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.8 p . . . . . 0 N--CA 1.467 0.392 0 N-CA-C 112.737 0.643 . . . . 2.15 112.737 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.487 HG23 ' HB3' ' A' ' 10' ' ' SER . 3.7 t 36.85 65.37 2.35 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 124.377 1.071 . . . . 2.43 113.203 179.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -59.2 132.37 46.45 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.727 2.285 . . . . 1.23 111.718 175.466 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.452 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 122.14 -47.17 1.04 Allowed Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.265 -1.134 . . . . 1.17 110.265 -171.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -164.67 105.8 0.84 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.894 -0.41 . . . . 3.96 109.894 175.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.487 ' HB3' HG23 ' A' ' 6' ' ' THR . 86.8 p . . . . . 0 C--N 1.322 -0.617 0 N-CA-C 108.798 -0.816 . . . . 2.86 108.798 176.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.441 0 N-CA-C 111.838 -0.505 . . . . 1.81 111.838 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.1 t -135.69 -86.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 2.01 110.157 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.452 ' C ' ' H ' ' A' ' 8' ' ' GLY . . . 82.3 109.99 0.43 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.79 -0.719 . . . . 2.1 111.892 -177.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 4.0 p80 . . . . . 0 C--O 1.245 0.816 0 CA-C-O 118.378 -0.82 . . . . 5.86 109.873 -179.636 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.182 0 CA-C-O 120.438 0.161 . . . . 1.85 110.919 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -66.69 -53.43 33.7 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.043 0.449 . . . . 2.97 110.364 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.496 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 5.1 pm0 . . . . . 0 N--CA 1.445 -0.681 0 CA-C-N 115.9 -0.591 . . . . 2.12 109.785 176.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p . . . . . 0 N--CA 1.465 0.312 0 N-CA-C 110.547 -0.168 . . . . 2.15 110.547 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.468 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 2.9 t -41.3 109.95 0.7 Allowed Pre-proline 0 CA--C 1.539 0.554 0 O-C-N 123.602 0.564 . . . . 2.43 111.763 177.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.491 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 2.7 Cg_exo -75.98 -166.96 0.4 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.937 2.425 . . . . 1.23 112.79 -177.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.0 24.17 62.3 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.98 -0.628 . . . . 1.17 111.696 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 62.12 28.35 17.08 Favored 'General case' 0 C--N 1.333 -0.151 0 C-N-CA 122.748 0.419 . . . . 3.96 111.372 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.9 m . . . . . 0 CA--C 1.537 0.472 0 CA-C-N 116.356 -0.384 . . . . 2.86 111.404 179.21 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 N-CA-C 111.826 -0.51 . . . . 1.81 111.826 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.3 p -138.35 166.43 23.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.969 -0.382 . . . . 2.01 109.969 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.15 159.16 10.16 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.034 -0.603 . . . . 2.1 112.002 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 7.9 p80 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.454 -0.784 . . . . 5.86 110.269 -178.072 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.06 0 N-CA-C 110.094 -0.336 . . . . 1.85 110.094 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -61.75 -29.44 70.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.735 0.302 . . . . 2.97 110.936 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 . . . . . 0 C--N 1.325 -0.498 0 N-CA-C 109.765 -0.457 . . . . 2.12 109.765 175.127 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 43.6 p . . . . . 0 N--CA 1.468 0.461 0 N-CA-C 112.155 0.428 . . . . 2.15 112.155 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.499 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 4.5 t -40.42 105.85 0.39 Allowed Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 123.948 0.78 . . . . 2.43 111.784 -177.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.577 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 13.9 Cg_exo -71.17 83.79 0.94 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.106 2.538 . . . . 1.23 114.357 -170.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.81 -22.04 44.33 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 110.721 -0.952 . . . . 1.17 110.721 168.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.8 m120 74.68 92.2 0.08 Allowed 'General case' 0 N--CA 1.465 0.318 0 C-N-CA 123.749 0.82 . . . . 3.96 111.915 174.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 59.7 m . . . . . 0 CA--C 1.541 0.608 0 CA-C-N 116.055 -0.521 . . . . 2.86 111.943 174.798 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.643 0 N-CA-C 111.545 -0.622 . . . . 1.81 111.545 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -84.18 47.94 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.444 0.64 . . . . 2.01 111.617 -177.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.577 ' CA ' ' HA ' ' A' ' 7' ' ' PRO . . . 152.14 -159.84 28.57 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.558 -0.829 . . . . 2.1 112.734 177.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 51.1 t-80 . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.27 -0.872 . . . . 5.86 111.15 -177.959 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 120.688 0.28 . . . . 1.85 110.758 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -63.5 -51.04 67.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.049 0.452 . . . . 2.97 110.048 178.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 . . . . . 0 C--N 1.325 -0.476 0 CA-C-N 115.801 -0.636 . . . . 2.12 109.52 174.781 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 35.8 p . . . . . 0 N--CA 1.468 0.471 0 N-CA-C 113.542 0.941 . . . . 2.15 113.542 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 10' ' ' SER . 41.2 p 47.4 82.53 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 115.621 -0.718 . . . . 2.43 112.105 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -79.33 -158.53 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.812 2.341 . . . . 1.23 111.753 -178.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.63 56.89 5.74 Favored Glycine 0 N--CA 1.447 -0.627 0 C-N-CA 120.352 -0.928 . . . . 1.17 111.903 -176.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 56.1 t30 50.88 64.94 1.63 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.18 0.514 . . . . 3.96 111.283 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.416 ' HB2' ' O ' ' A' ' 6' ' ' THR . 46.1 m . . . . . 0 C--N 1.322 -0.601 0 CA-C-N 116.303 -0.408 . . . . 2.86 111.087 175.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.547 0 N-CA-C 111.978 -0.449 . . . . 1.81 111.978 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.8 m -83.59 47.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.407 0.622 . . . . 2.01 111.702 -177.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.52 130.72 10.0 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.798 -0.715 . . . . 2.1 111.944 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 . . . . . 0 C--O 1.247 0.921 0 CA-C-O 118.795 -0.622 . . . . 5.86 109.777 -178.512 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.175 0 N-CA-C 109.92 -0.4 . . . . 1.85 109.92 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -70.6 -31.72 68.81 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 108.646 -0.872 . . . . 2.97 108.646 171.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 . . . . . 0 N--CA 1.445 -0.685 0 N-CA-C 107.927 -1.138 . . . . 2.12 107.927 168.889 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.0 p . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 121.676 0.751 . . . . 2.15 111.966 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.6 t 175.96 104.98 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 114.415 -1.266 . . . . 2.43 108.546 176.092 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.558 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 8.7 Cg_endo -97.49 171.74 0.74 Allowed 'Trans proline' 0 CA--C 1.533 0.437 0 C-N-CA 123.702 2.935 . . . . 1.23 113.786 178.384 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.49 1.8 63.93 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.936 -0.574 . . . . 1.17 113.637 172.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.1 p30 172.71 39.38 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 108.69 -0.856 . . . . 3.96 108.69 -176.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.558 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.1 m . . . . . 0 C--N 1.312 -1.044 0 CA-C-N 114.804 -1.089 . . . . 2.86 112.461 -164.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.542 0 N-CA-C 112.196 -0.361 . . . . 1.81 112.196 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.35 -85.13 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 120.688 0.28 . . . . 2.01 110.961 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.08 165.57 37.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.942 -0.647 . . . . 2.1 112.493 -178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 . . . . . 0 C--O 1.246 0.902 0 CA-C-O 118.097 -0.954 . . . . 5.86 110.321 179.106 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.033 0 CA-C-O 120.754 0.311 . . . . 1.85 110.977 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -73.81 -37.48 64.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.455 -0.339 . . . . 2.97 111.468 -176.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.416 ' C ' ' H ' ' A' ' 5' ' ' THR . 0.6 OUTLIER -87.42 134.46 33.59 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.059 -0.349 . . . . 2.12 110.059 178.804 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.416 ' H ' ' C ' ' A' ' 3' ' ' GLN . 82.1 p 53.13 17.15 0.9 Allowed 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 125.087 1.355 . . . . 2.15 113.432 177.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -141.39 72.86 25.78 Favored Pre-proline 0 C--N 1.309 -1.156 0 CA-C-N 115.26 -0.882 . . . . 2.43 110.498 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.45 162.12 43.17 Favored 'Trans proline' 0 C--O 1.234 0.288 0 C-N-CA 123.218 2.612 . . . . 1.23 112.238 -175.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 83.76 31.08 27.69 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.591 -0.814 . . . . 1.17 112.228 -176.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.7 p30 41.01 42.43 1.53 Allowed 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.231 1.012 . . . . 3.96 113.039 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.516 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 14.4 m -61.66 -47.37 85.65 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 116.5 -0.318 . . . . 2.86 111.421 178.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.516 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.84 -49.22 1.28 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.965 -0.636 . . . . 1.81 112.437 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.12 133.33 53.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 110.047 -0.353 . . . . 2.01 110.047 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.09 -173.4 43.55 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.918 -0.658 . . . . 2.1 111.604 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 76.1 t60 . . . . . 0 C--O 1.242 0.699 0 CA-C-O 118.561 -0.733 . . . . 5.86 109.76 179.252 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.132 0 CA-C-O 120.423 0.154 . . . . 1.85 110.975 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -66.25 -41.3 90.13 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-O 121.195 0.521 . . . . 2.97 110.33 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.595 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER -91.57 124.46 35.74 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.599 -0.728 . . . . 2.12 109.395 175.843 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p 60.56 163.92 0.07 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 124.632 1.173 . . . . 2.15 112.539 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.7 p 45.5 68.5 3.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 113.044 0.757 . . . . 2.43 113.044 178.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.48 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.9 Cg_exo -59.39 118.68 5.6 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.868 2.379 . . . . 1.23 111.914 177.283 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.3 -35.07 2.66 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.507 -0.769 . . . . 1.17 111.196 -177.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.2 t30 -171.17 107.57 0.27 Allowed 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 109.962 -0.384 . . . . 3.96 109.962 177.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.455 ' HB2' ' HD ' ' A' ' 11' ' ' HZP . 21.9 p -141.78 167.15 22.84 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 2.86 109.992 -179.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.455 ' HD ' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.26 -67.97 1.78 Allowed Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.63 -0.795 . . . . 1.81 111.372 176.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.646 HG13 ' H ' ' A' ' 14' ' ' GLY . 2.7 p -166.78 -65.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 110.063 -0.347 . . . . 2.01 110.063 175.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.646 ' H ' HG13 ' A' ' 13' ' ' VAL . . . 78.29 130.63 0.59 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.779 -0.724 . . . . 2.1 112.689 177.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 . . . . . 0 C--O 1.246 0.873 0 CA-C-O 118.597 -0.716 . . . . 5.86 109.849 -178.127 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.121 0 CA-C-O 120.684 0.278 . . . . 1.85 110.49 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -69.38 -38.74 78.15 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 121.775 0.797 . . . . 2.97 109.138 176.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.582 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.2 OUTLIER -96.33 157.18 16.02 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-N 114.254 -1.339 . . . . 2.12 109.384 177.104 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.54 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 66.8 p 60.66 -173.18 0.13 Allowed 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 124.791 1.236 . . . . 2.15 112.679 178.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 t -48.49 113.47 2.92 Favored Pre-proline 0 CA--C 1.535 0.402 0 C-N-CA 123.352 0.661 . . . . 2.43 112.316 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.57 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 69.2 Cg_exo -57.5 156.63 25.7 Favored 'Trans proline' 0 C--N 1.348 0.516 0 C-N-CA 123.342 2.695 . . . . 1.23 113.094 176.358 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.95 -39.58 2.7 Favored Glycine 0 N--CA 1.447 -0.626 0 CA-C-N 115.425 -0.807 . . . . 1.17 111.885 -177.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -133.29 24.96 4.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.529 0.681 . . . . 3.96 109.914 -177.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.57 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.3 m -76.58 149.46 36.61 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.271 -0.877 . . . . 2.86 111.191 -176.234 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.32 -66.15 0.28 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.737 -0.744 . . . . 1.81 112.374 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.5 t -97.32 -68.4 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 110.22 -0.289 . . . . 2.01 110.22 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 66.68 49.36 56.04 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.716 -0.754 . . . . 2.1 113.131 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 73.5 t60 . . . . . 0 C--O 1.244 0.796 0 CA-C-O 118.474 -0.774 . . . . 5.86 109.943 177.245 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 120.652 0.263 . . . . 1.85 110.802 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -129.56 25.2 5.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.349 0.595 . . . . 2.97 109.879 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 13.3 pm0 -130.58 147.01 52.21 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.56 -0.746 . . . . 2.12 109.629 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.412 ' O ' HG22 ' A' ' 6' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.8 p 56.33 28.13 12.96 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.393 1.077 . . . . 2.15 111.994 -178.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.412 HG22 ' O ' ' A' ' 4' ' ' HZP . 4.3 t 176.05 103.56 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.99 -1.004 . . . . 2.43 110.086 178.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -81.45 -171.42 1.21 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.859 2.373 . . . . 1.23 112.149 175.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 90.09 -1.45 80.22 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 121.019 -0.61 . . . . 1.17 112.714 178.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 60.66 71.76 0.55 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.232 0.539 . . . . 3.96 110.597 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.54 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 19.0 m -114.57 -53.24 2.67 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.0 -0.546 . . . . 2.86 111.631 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.54 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 140.83 -58.86 0.57 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.869 -0.682 . . . . 1.81 112.279 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.61 163.88 17.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 110.087 -0.338 . . . . 2.01 110.087 -179.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.92 152.48 5.65 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 111.426 -0.67 . . . . 2.1 111.426 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.672 -0.68 . . . . 5.86 109.825 -178.215 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.039 0 CA-C-O 120.579 0.228 . . . . 1.85 110.967 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -113.58 -72.4 0.71 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.128 0.489 . . . . 2.97 109.884 179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.566 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 0.0 OUTLIER -97.11 146.05 25.41 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.649 -0.705 . . . . 2.12 109.48 175.989 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.466 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.6 p 70.06 -171.04 0.17 Allowed 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 125.18 1.392 . . . . 2.15 111.739 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.5 p -50.7 123.76 18.59 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.317 -0.401 . . . . 2.43 112.05 -177.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.537 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 51.8 Cg_exo -56.14 156.72 19.51 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.063 2.509 . . . . 1.23 112.517 176.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 95.5 82.74 1.61 Allowed Glycine 0 N--CA 1.445 -0.746 0 N-CA-C 111.408 -0.677 . . . . 1.17 111.408 -177.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 69.19 42.83 1.17 Allowed 'General case' 0 CA--C 1.52 -0.188 0 CA-C-O 121.566 0.698 . . . . 3.96 109.752 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.627 ' OG ' ' HA3' ' A' ' 14' ' ' GLY . 4.4 m -76.53 148.27 37.21 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.988 -1.006 . . . . 2.86 110.42 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 123.63 -70.87 0.44 Allowed Glycine 0 N--CA 1.446 -0.634 0 N-CA-C 111.349 -0.701 . . . . 1.81 111.349 -176.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.5 p -165.36 122.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.073 0.463 . . . . 2.01 110.497 177.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.627 ' HA3' ' OG ' ' A' ' 10' ' ' SER . . . -159.95 135.03 3.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.579 -0.82 . . . . 2.1 112.885 -178.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 69.6 m80 . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.353 -0.832 . . . . 5.86 109.838 177.958 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.986 0 N-CA-C 110.557 -0.164 . . . . 1.85 110.557 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 67.67 -75.82 0.06 Allowed 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 123.679 0.792 . . . . 2.97 111.258 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -80.09 126.33 30.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.439 -0.346 . . . . 2.12 110.345 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.8 p 57.78 -175.22 0.08 Allowed 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.445 1.098 . . . . 2.15 112.737 176.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.487 HG23 ' HB3' ' A' ' 10' ' ' SER . 3.7 t 36.85 65.37 2.35 Favored Pre-proline 0 CA--C 1.541 0.633 0 C-N-CA 124.377 1.071 . . . . 2.43 113.203 179.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -59.2 132.37 46.45 Favored 'Trans proline' 0 C--N 1.351 0.668 0 C-N-CA 122.727 2.285 . . . . 1.23 111.718 175.466 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.452 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 122.14 -47.17 1.04 Allowed Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.265 -1.134 . . . . 1.17 110.265 -171.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -164.67 105.8 0.84 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.894 -0.41 . . . . 3.96 109.894 175.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.487 ' HB3' HG23 ' A' ' 6' ' ' THR . 86.8 p -131.04 158.97 38.9 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.798 -0.816 . . . . 2.86 108.798 176.1 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.63 -74.48 0.69 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.819 -0.705 . . . . 1.81 111.838 177.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 40.1 t -135.69 -86.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 2.01 110.157 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.452 ' C ' ' H ' ' A' ' 8' ' ' GLY . . . 82.3 109.99 0.43 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.79 -0.719 . . . . 2.1 111.892 -177.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 4.0 p80 . . . . . 0 C--O 1.245 0.816 0 CA-C-O 118.378 -0.82 . . . . 5.86 109.873 -179.636 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.182 0 CA-C-O 120.438 0.161 . . . . 1.85 110.919 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -66.69 -53.43 33.7 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 121.043 0.449 . . . . 2.97 110.364 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.496 ' CD ' ' H ' ' A' ' 3' ' ' GLN . 5.1 pm0 -84.3 141.44 30.93 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-N 115.9 -0.591 . . . . 2.12 109.785 176.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p 55.34 -161.83 0.16 Allowed 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 123.602 0.761 . . . . 2.15 110.547 -175.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.506 ' O ' ' HDA' ' A' ' 11' ' ' HZP . 2.9 t -41.3 109.95 0.7 Allowed Pre-proline 0 CA--C 1.539 0.554 0 O-C-N 123.602 0.564 . . . . 2.43 111.763 177.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.491 ' HG3' ' HG3' ' A' ' 3' ' ' GLN . 2.7 Cg_exo -75.98 -166.96 0.4 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.937 2.425 . . . . 1.23 112.79 -177.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 79.0 24.17 62.3 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.98 -0.628 . . . . 1.17 111.696 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 62.12 28.35 17.08 Favored 'General case' 0 C--N 1.333 -0.151 0 C-N-CA 122.748 0.419 . . . . 3.96 111.372 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.507 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 15.9 m -65.75 -48.86 70.47 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.356 -0.384 . . . . 2.86 111.404 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.507 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 118.6 -38.1 3.0 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.401 -0.818 . . . . 1.81 111.826 -179.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.3 p -138.35 166.43 23.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.969 -0.382 . . . . 2.01 109.969 -177.265 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.15 159.16 10.16 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 121.034 -0.603 . . . . 2.1 112.002 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 7.9 p80 . . . . . 0 C--O 1.248 0.985 0 CA-C-O 118.454 -0.784 . . . . 5.86 110.269 -178.072 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.06 0 N-CA-C 110.094 -0.336 . . . . 1.85 110.094 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -61.75 -29.44 70.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.735 0.302 . . . . 2.97 110.936 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 -102.79 141.99 34.67 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.765 -0.457 . . . . 2.12 109.765 175.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 43.6 p 67.56 -171.8 0.19 Allowed 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 124.438 1.095 . . . . 2.15 112.155 171.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.499 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 4.5 t -40.42 105.85 0.39 Allowed Pre-proline 0 CA--C 1.537 0.458 0 O-C-N 123.948 0.78 . . . . 2.43 111.784 -177.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.577 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 13.9 Cg_exo -71.17 83.79 0.94 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 123.106 2.538 . . . . 1.23 114.357 -170.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.81 -22.04 44.33 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 110.721 -0.952 . . . . 1.17 110.721 168.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.8 m120 74.68 92.2 0.08 Allowed 'General case' 0 N--CA 1.465 0.318 0 C-N-CA 123.749 0.82 . . . . 3.96 111.915 174.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.537 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 59.7 m -143.05 -54.37 0.4 Allowed 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 116.055 -0.521 . . . . 2.86 111.943 174.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.573 ' HD ' ' O ' ' A' ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.46 -138.08 4.93 Favored Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.674 -0.694 . . . . 1.81 111.545 -177.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -84.18 47.94 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.444 0.64 . . . . 2.01 111.617 -177.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.577 ' CA ' ' HA ' ' A' ' 7' ' ' PRO . . . 152.14 -159.84 28.57 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.558 -0.829 . . . . 2.1 112.734 177.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 51.1 t-80 . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.27 -0.872 . . . . 5.86 111.15 -177.959 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.985 0 CA-C-O 120.688 0.28 . . . . 1.85 110.758 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -63.5 -51.04 67.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.049 0.452 . . . . 2.97 110.048 178.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -78.5 135.9 37.46 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.801 -0.636 . . . . 2.12 109.52 174.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.492 ' O ' ' HG ' ' A' ' 11' ' ' HZP . 35.8 p 53.01 99.71 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.415 1.086 . . . . 2.15 113.542 170.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 10' ' ' SER . 41.2 p 47.4 82.53 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 115.621 -0.718 . . . . 2.43 112.105 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -79.33 -158.53 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.812 2.341 . . . . 1.23 111.753 -178.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.63 56.89 5.74 Favored Glycine 0 N--CA 1.447 -0.627 0 C-N-CA 120.352 -0.928 . . . . 1.17 111.903 -176.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 56.1 t30 50.88 64.94 1.63 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.18 0.514 . . . . 3.96 111.283 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.577 ' HB2' ' HDA' ' A' ' 11' ' ' HZP . 46.1 m -130.72 -52.87 1.07 Allowed 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.303 -0.408 . . . . 2.86 111.087 175.577 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . 0.577 ' HDA' ' HB2' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.85 -85.39 1.51 Allowed Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.929 -0.653 . . . . 1.81 111.978 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.8 m -83.59 47.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.407 0.622 . . . . 2.01 111.702 -177.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.52 130.72 10.0 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.798 -0.715 . . . . 2.1 111.944 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 . . . . . 0 C--O 1.247 0.921 0 CA-C-O 118.795 -0.622 . . . . 5.86 109.777 -178.512 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.175 0 N-CA-C 109.92 -0.4 . . . . 1.85 109.92 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 36.1 p90 -70.6 -31.72 68.81 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 108.646 -0.872 . . . . 2.97 108.646 171.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -117.83 111.73 19.44 Favored 'General case' 0 N--CA 1.445 -0.685 0 N-CA-C 107.927 -1.138 . . . . 2.12 107.927 168.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' HZP . . . . . 0.436 ' OD1' ' HB3' ' A' ' 10' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.0 p 51.85 32.36 9.65 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 124.298 1.039 . . . . 2.15 111.966 -178.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.433 HG22 ' O ' ' A' ' 4' ' ' HZP . 3.6 t 175.96 104.98 0.1 OUTLIER Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 114.415 -1.266 . . . . 2.43 108.546 176.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.558 ' HA ' ' OG ' ' A' ' 10' ' ' SER . 8.7 Cg_endo -97.49 171.74 0.74 Allowed 'Trans proline' 0 CA--C 1.533 0.437 0 C-N-CA 123.702 2.935 . . . . 1.23 113.786 178.384 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 94.49 1.8 63.93 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.936 -0.574 . . . . 1.17 113.637 172.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.1 p30 172.71 39.38 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 108.69 -0.856 . . . . 3.96 108.69 -176.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.558 ' OG ' ' HA ' ' A' ' 7' ' ' PRO . 1.1 m -97.01 143.22 28.07 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.804 -1.089 . . . . 2.86 112.461 -164.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' HZP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.79 -86.65 1.46 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.697 -0.763 . . . . 1.81 112.196 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.35 -85.13 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 120.688 0.28 . . . . 2.01 110.961 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.08 165.57 37.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.942 -0.647 . . . . 2.1 112.493 -178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' HIS . . . . . . . . . . . . . 59.3 t-80 . . . . . 0 C--O 1.246 0.902 0 CA-C-O 118.097 -0.954 . . . . 5.86 110.321 179.106 . . . . . . . . 0 0 . 1 stop_ save_